Toggle light / dark theme

Scientists at the University of Colorado Anschutz Medical Campus have discovered what they believe to be the central mechanism behind cognitive decline associated with normal aging.

“The mechanism involves the mis-regulation of a brain protein known as CaMKII which is crucial for memory and learning,” said the study’s co-senior author Ulli Bayer, PhD, professor of pharmacology at the University of Colorado School of Medicine. “This study directly suggests specific pharmacological treatment strategies.”

The study was published today in the journal ‘Science Signaling.’

Crohn’s disease affects four million people worldwide. The condition causes debilitating symptoms such as chronic fatigue, diarrhoea, abdominal pain, weight loss and malnutrition.

Once symptoms develop, Crohn’s is a lifelong condition – and while there are ways to manage symptoms during flare-ups, there’s currently no cure.

The exact causes of Crohn’s disease are unknown and are probably due to a number of complex and overlapping factors – such as genetics, environmental cues (such as smoking) and an immune system that’s overactive in the gut.

Reduction in blood oxygen levels, largely attributed to blocked airways, emerges as a leading factor.

Researchers have found that people with obstructive sleep apnea have an increased cardiovascular risk due to reduced blood oxygen levels, largely explained by interrupted breathing. Obstructive sleep apnea has long been associated with increased risk of cardiovascular issues, including heart attack, stroke, and death, but the findings from this study, partially supported by the National Institutes of Health and published in the American Journal of Respiratory and Critical Care Medicine, show the mechanism mostly responsible for the link.

“These findings will help better characterize high-risk versions of obstructive sleep apnea,” said Ali Azarbarzin, Ph.D., a study author and director of the Sleep Apnea Health Outcomes Research Group at Brigham and Women’s Hospital and Harvard Medical School, Boston. “We think that including a higher-risk version of obstructive sleep apnea in a randomized clinical trial would hopefully show that treating sleep apnea could help prevent future cardiovascular outcomes.”